Eyerich, K., Weisenseel, P., Pinter, A., Schäkel, K., Asadullah, K., Wegner, S., . . . Reich, K. (2021). IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: Rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ open, 11(9), . https://doi.org/10.1136/bmjopen-2021-049822
Chicago-Zitierstil (17. Ausg.)Eyerich, Kilian, et al. "IL-23 Blockade with Guselkumab Potentially Modifies Psoriasis Pathogenesis: Rationale and Study Protocol of a Phase 3b, Randomised, Double-blind, Multicentre Study in Participants with Moderate-to-severe Plaque-type Psoriasis (GUIDE)." BMJ Open 11, no. 9 (2021). https://doi.org/10.1136/bmjopen-2021-049822.
MLA-Zitierstil (9. Ausg.)Eyerich, Kilian, et al. "IL-23 Blockade with Guselkumab Potentially Modifies Psoriasis Pathogenesis: Rationale and Study Protocol of a Phase 3b, Randomised, Double-blind, Multicentre Study in Participants with Moderate-to-severe Plaque-type Psoriasis (GUIDE)." BMJ Open, vol. 11, no. 9, 2021, https://doi.org/10.1136/bmjopen-2021-049822.